Alto Neuroscience (NYSE:ANRO) Shares Up 6.5% – Time to Buy?

Alto Neuroscience, Inc. (NYSE:ANRO)’s share price was up 6.5% during mid-day trading on Tuesday . The stock traded as high as $24.18 and last traded at $24.4190. 31,965 shares changed hands during trading, a decline of 89% from the average session volume of 288,659 shares. The stock had previously closed at $22.93.

Wall Street Analysts Forecast Growth

ANRO has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Chardan Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a report on Wednesday, April 22nd. Robert W. Baird reduced their price target on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. HC Wainwright restated a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Finally, Bank of America assumed coverage on Alto Neuroscience in a research report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Price Performance

The company’s 50-day moving average is $22.74 and its 200-day moving average is $19.92. The firm has a market capitalization of $889.77 million, a price-to-earnings ratio of -10.47 and a beta of 1.24. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). On average, research analysts expect that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ANRO. Quantinno Capital Management LP grew its position in Alto Neuroscience by 1.4% during the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock valued at $811,000 after acquiring an additional 490 shares during the period. Peapod Lane Capital LLC raised its holdings in shares of Alto Neuroscience by 1.1% in the 3rd quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock worth $1,136,000 after purchasing an additional 3,106 shares during the period. Torren Management LLC acquired a new position in shares of Alto Neuroscience in the 4th quarter valued at about $62,000. XTX Topco Ltd lifted its stake in shares of Alto Neuroscience by 32.2% in the 4th quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock valued at $371,000 after purchasing an additional 5,078 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Alto Neuroscience by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock valued at $2,327,000 after purchasing an additional 6,100 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.